<DOC>
	<DOCNO>NCT01574027</DOCNO>
	<brief_summary>Vitamin D 's ability prevent colorectal cancer ( CRC ) suspect nearly 30 year , never directly study human . The biologically active version vitamin D , 1,25 ( OH ) 2D3 , readily use human tendency cause serum calcium level rise . In contrast , 25 ( OH ) D3 ( ie calcifediol ) side effect . The investigator previous research suggest enzyme necessary convert 25 ( OH ) D3 ( calcifediol ) active 1,25 ( OH ) D3 present cell line large intestine ( colon ) . Aberrant crypt focus ( ACF ) small ( ie microscopic ) collection abnormally shape cell commonly use marker CRC risk . Screening colonoscopy UIC routinely use method allow ACF count do part standard practice . ACF 's fix , like polyp cancer , disappear person 's risk develop CRC decrease . The investigator propose give patient 's 10 ACF 's 25 ( OH ) D3 ( calcifediol ) placebo , determine drug-dependant decrease ACF number . The primary objective determine whether 25 ( OH ) D3 ( calcifediol ) supplementation , compare placebo , cause significant reduction ACF number baseline level . The primary endpoint change ACF number .</brief_summary>
	<brief_title>Efficacy Vitamin D Colorectal Cancer Chemoprevention</brief_title>
	<detailed_description>Patients offer participation study time regularly schedule visit UIC Colorectal Cancer Screening Clinic . Those agree indicate understanding participation conditional upon 10+ ACF time screen colonoscopy . If screen colonoscopy 10+ ACF find patient : - undergo 3 endoscopic mucosal biopsy distal colon ; - undergo blood draw i.v . already place sedative-narcotic administration serum 25 ( OH ) D3 serum ionized calcium ; - give either placebo calcifediol instruct take daily 6 month . - provide urine calcium/creatine spot ratio . At 7 14 day screen colonoscopy patient call telephone clinical research nurse assign study follow-up note 25 ( OH ) D3 ( calcifediol ) toxicity , ( note toxicity describe except case overdose ) . Signs specifically look include : headache , increased urination , nausea , vomit , abdominal pain , weakness , constipation , anorexia . If present , patient advise present immediately UIC GCRC physical serological evaluation . At 30 , 90 120 day patient agree present GCRC clinic : - Capsule retrieval/count ( 80 % compliance require remain study ) ; - Detailed history physical , focus specifically sign symptom hypercalcemia . - At day 90 - provide urine calcium/creatine spot ratio . Evidence exam , laboratory , hypercalcemia result adverse event report immediate patient discharge study . Signs specifically look include : headache , increased urination , nausea , vomit , abdominal pain , weakness , constipation , anorexia . At 180 day patient agree undergo : - Repeat endoscopic exam limit recto-sigmoid colon , also know `` flexible sigmoidoscopy '' ; - repeat blood draw serum 25 ( OH ) D3 serum ionize calcium</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>All nonpregnant patient 50 year age old 10 ACFs . The follow specifically look , result patient eligible study enrollment : Use nonsteroidal antiinflammatory drug glucocorticosteroids within 60 day study entry . History chronic IBD prior pelvic radiation ( inflammation distort crypt pattern ) . Intake vitamin D calcium supplement within 60 day study entry . Patients increase bleed risk biopsy protocol ( i.e . renal failure , decompensated cirrhosis , blood dyscrasia</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Assess efficacy vitamin D prevent colorectal cancer identify population likely ( unlikely ) benefit vitamin D-based therapy .</keyword>
	<keyword>Evaluate ability Vitamin D3 ( cholecalciferol ) reduce ACF 's human .</keyword>
</DOC>